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Abstract
Background: Langerhans cell histiocytosis (LCH) features inflammatory granuloma characterised by the presence of CD1a+
dendritic cells or ‘LCH cells’. Badalian-Very et al. recently reported the presence of a canonical
V600EB-RAF mutation in 57% of
paraffin-embedded biopsies from LCH granuloma. Here we confirm their findings and report the identification of two novel
B-RAF mutations detected in LCH patients.
Methods and Results: Mutations of B-RAF were observed in granuloma samples from 11 out of 16 patients using ‘next
generation’ pyrosequencing. In 9 cases the mutation identified was
V600EB-RAF. In 2 cases novel polymorphisms were
identified. A somatic
600DLATB-RAF insertion mimicked the structural and functional consequences of the
V600EB-RAF mutant.
It destabilized the inactive conformation of the B-RAF kinase and resulted in increased ERK activation in 293 T cells. The
600DLATB-RAF and
V600EB-RAF mutations were found enriched in DNA and mRNA from the CD1a+ fraction of granuloma. They
were absent from the blood and monocytes of 58 LCH patients, with a lower threshold of sequencing sensitivity of 1%–2%
relative mutation abundance. A novel germ line
T599AB-RAF mutant allele was detected in one patient, at a relative mutation
abundance close to 50% in the LCH granuloma, blood monocytes and lymphocytes. However,
T599AB-RAF did not
destabilize the inactive conformation of the B-RAF kinase, and did not induce increased ERK phosphorylation or C-RAF
transactivation.
Conclusions: Our data confirmed presence of the
V600EB-RAF mutation in LCH granuloma of some patients, and identify two
novel B-RAF mutations. They indicate that
V600EB-RAF and
600DLATB-RAF mutations are somatic mutants enriched in LCH
CD1a
+ cells and absent from the patient blood. Further studies are needed to assess the functional consequences of the
germ-line
T599AB-RAF allele.
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Introduction
Langerhans cell histiocytosis (LCH) is a pediatric granulomatous
disease with an incidence of four to eight cases per million children
[1,2,3]. The clinical spectrum of LCH is remarkably broad,
ranging from isolated skin or bone lesions to a disseminated disease
that may require aggressive chemotherapy [1,4,5]. LCH can lead
to severe dental and periodontal lesions [6]. LCH also frequently
leads to diabetes insipidus [1,2,3]. Apart from diabetes insipidus,
central nervous system involvement in Langerhans cell histiocy-
tosis (LCH) is rare but represent a serious complication with
neurological deterioration, including progressive cerebellar ataxia
[7].
LCH lesions feature granulomatous collections of immature
CD1a+ langerin/CD207+ DC (‘LCH cells’) presumed to be
pathologic [8,9,10], admixed with abundant eosinophils [11],
polyclonal T cells including abundant FoxP3
+ CD4
+ T cells [12],
activated macrophages and osteoclast-like multinucleated giant
cells [13]. These granuloma are therefore heterogeneous in
cellular composition as well as anatomical distribution. The
pathophysiology of LCH is largely unknown [10,14], although a
genetic component is suggested by a higher concordance rate
between monozygotic twins compared with dizygotic twins [15].
The tropism of skin lesions to flexures also suggests that external
stimuli may trigger inflammation [16]. However, the nature of the
initiating event(s), and the mechanisms of local tissue destruction
by LCH and other inflammatory cells are still largely unknown.
Clonality of LCH granulomas has been reported in 1994
[17,18]. Its significance remained controversial, since specific
genetic abnormalities were not consistently observed [19], until
recently. Progress came from the identification by Badalian-Very
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V600EB-RAF mutation by pyrosequencing of formalin-
fixed, paraffin-embedded material, from 35 out of 61 archived
specimens (57%) [20]. This
V600EB-RAF mutation is likely to be
somatic, because a germ-line activating
V600EB-RAF allele is
embryonic lethal in mice [21]. B-RAF is a protein kinase activated
by ras-coupled receptor tyrosine kinases (RTK) that is central to
signaling via the Mitogen Activated Kinase (MAPK) and
phosphorylates its downstream target MEK and ERK kinases
[22]. The RAS-RAF-MAPK pathway coordinates a large variety
of cellular responses involved in development, cell cycle regulation,
cell proliferation and differentiation, cell survival and apoptosis,
and many other physiological processes, by transmitting extracel-
lular signals to various nuclear, cytoplasmic and membrane-bound
targets [22].
Data obtained from murine model using Cre-mediated
activation of a conditionnal B-RAF allele indicate that
V600EB-
RAF can contribute to tumour initiation [23]. For example,
V600EB-RAF induces high levels of cyclin D1-mediated cell
proliferation. However,
V600EB-RAF also induces oncogene-
induced senescence (OIS) that may restrain further development
of the tumour [23,24]. In human, somatic
V600EB-RAF mutation
have been found in a number of benign and malignant tumors
including non-malignant naevi [25], melanoma [26], colon and
thyroid tumors [21,22,24,26]. Thus
V600EB-RAF may represent a
first step toward the development of a malignant tumor, although
the presence of a
V600EB-RAF mutation is not synonymous with
cancer.
Of note, the clinical features of LCH are not typical of cancer
[10,14] and LCH lesions frequently regress, either spontaneously
or after local treatment [1,4,5]. In addition, LCH CD1a+ cells,
which are presumed to be pathologic, very slowly proliferate in
most patients [12], while the expansion of a monocyte or dendritic
cell compartment, which represent candidate precursors for these
CD1a+ cells of the granuloma, was not consistently observed in
the blood of LCH patients [12,27].
Identification of dysregulation of the RAS-RAF-MAPK path-
way in LCH is nevertheless an important step towards a molecular
understanding of the pathophysiology of this pediatric granuloma.
It suggests possible novel therapeutic approaches, e.g. the use of B-
RAF or MEK inhibitors. Moreover, if
V600EB-RAF was detectable
in the patient’s blood, this could be of use for diagnostic,
monitoring of treatment efficacy, and potentially prognostic
purposes.
We therefore sought firstly to confirm the finding of Badalian-
Very using another methodology i.e. analyzing flow sorted CD1a+
cells from fresh LCH granuloma tissue instead of paraffin
embedded biopsies. We then aimed to compare relative mutation
abundance of V600E B-RAF mutations between CD1a+ and
CD1a2 cells from LCH granuloma, and whether mutations can
be detected in the peripheral blood of patients. Finally we
investigated whether additional B-RAF mutations can be found in
LCH patients, to further reinforce the link between LCH and the
RAS-RAF pathway.
Results
B-RAF polymorphisms associated with LCH
We investigated the presence of B-RAF mutations by ‘next
generation’ pyrosequencing (Roche GS FLX 454) in a series of 16
granuloma samples obtained at diagnosis from 16 patients with
LCH from a cohort followed in the French LCH Registry (Tables 1
& 2). Among granuloma samples 11/16 carried B-RAF mutations
as detected by pyrosequencing of granuloma genomic DNA
(gDNA) and cDNA (Table 1). In 9/11 cases (patients #1–9) we
found a g1799 T.A transition resulting in the previously
described
V600EB-RAF mutation [20] (Figure 1 A). In one patient
(patient #10) we found a novel in-frame insertion of 12
nucleotides, leading to the insertion of 4 amino acids (Asp-Leu-
Ala-Thr, or DLAT) (Figure 1 A). In one other patient we observed
an A.G transversion, producing a
T599AB-RAF allele (Table 2,
Figure 1 A). The
T599AB-RAF and
600DLATB-RAF alleles were not
previously reported in the literature, dbSNP (v131), or in data
from 1000 genomes project (Nov 10 release).
Somatic B-RAF mutations
The
V600EB-RAF and
600DLATB-RAF, mutations were detected
in granuloma from patients 1–10 with a high relative mutation
abundance (RMA) (Table 2) We therefore investigated whether
these alleles were germ-line or somatic mutants, and which cellular
fraction of the granuloma was bearing the mutation. In 4 cases of
V600EB-RAF mutation (Patients 4, 5, 8, 9) and in the sample
carrying the
600DLATB-RAF mutation (patient #10) (Table 2),
CD1a+ cells were enriched from fresh granuloma tissue using
antibody-coupled beads [8]. The CD1a-depleted fractions (Efflu-
ent, Table 2) were also collected in 4 cases (Patients 5, 8, 9, 10,
Table 2). Genomic DNA and cDNA were extracted from all
samples and analysed by next generation sequencing. In all cases
B-RAF mutated alleles were enriched in the CD1a+ fraction at the
genomic DNA and cDNA level, in comparison with the CD1a-
depleted fractions, with a relative mutation abundance of up to
48% (Table 2), suggesting that the CD1a+ ‘LCH cells’ carry a
heterozygous B-RAF mutant allele, though we did not assess
heterozygosity at the single cell level. We then investigated
whether
V600EB-RAF or
600DLATB-RAF mutations could be found
in the patients circulating myeloid or lymphoid cells, either
because of a germ-line mutation, or because of a mosaicism in
bone marrow progenitors. Analysis by pyrosequencing of whole
blood and of purified monocytes (CD14+) and lymphocytes
(CD142) from patient 1 indicated the absence of detectable B-
RAF mutations, with a lower threshold of sequencing sensitivity of
1%–2% relative mutation abundance. Analysis of whole blood
from patient 2 with the same method also failed to detect a
V600EB-
RAF mutation. Blood samples were not available for the 8 other
patients with a
V600EB-RAF or
600DLATB-RAF mutation.
We therefore investigated the presence of B-RAF mutations in
peripheral blood mononuclear cells of an additional series of LCH
patients for whom blood samples were available either at diagnosis
or relapse (n=22) (Table 3), or under treatment (n=32). Neither
V600EB-RAF or
600DLATB-RAF were detectable by pyrosequencing
in these 56 peripheral blood mononuclear cell samples (Tables 2 &
3, and data not shown). Unfortunately granuloma samples were
not availables for these patients, however based on the frequency
of B-RAF mutation in LCH granuloma, 57% in the Badalian-
Very study, and 11/16 (68%) in the present study, it is likely that
several of the 56 patients had a B-RAF mutation in their
granuloma.
In aggregate, these data indicate that
V600EB-RAF and
600DLATB-RAF mutations are detectable in granuloma but not in
the blood, and thus strongly suggest they are somatic events. In
addition, lack of detection of B-RAF mutations in the blood from
patients 1 and 2 and from the 22 others patients for whom blood
samples were available at diagnosis or relapse suggests that
detection of potential circulating B-RAF mutated cells will require
a threshold of sensitivity below 1%.
Germline B-RAF polymorphisms
In contrast, the
T599AB-RAF mutation was detected in both the
granuloma and the whole blood of patient #16.
T599AB-RAF was
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e33891Figure 1. Analysis of B-RAF mutant. A. Sequence alignment, results from 454 pyrosequencing of granuloma cells from patients 1–10 and 16. B.
‘Sanger’ sequencing of patient 16 blood; A/G transition at nucleotide 1795. C. Pedigree of patient 16. Both the patient and his mother carry a
T599AB-
RAF allele, while his father is
wtB-RAF. D–E. Comparison between
wtB-RAF 5P_15056 (D, purple),
V600EB-RAF structure (E, cyan) and the modeled
mutant
600DLATB-RAF (F, grey). In D, Val600 (yellow) forms a hydrophobic contact with Phe468 (red arrow). In E and F charged residues Asp and Glu (in
orange) disrupt the hydrophobic network of interactions, stabilising the active conformation of the P-loop. In F, insertion Asp-Leu-Ala-Thr shifted
Val600 and disrupt the hydrophobic cluster. G, H. MEK phosphorylation in 293 T cells. 293 T cells were transiently transfected with with mock or B-
RAF mutant expressing vectors (WT, V600E, T599A, 600DLAT, D594A, G596R), and with (H) or without (G) wtC-RAF. Twenty-four hours after
transfection, the medium was changed to serum-free DMEM, followed by further 18 hours culture. Total cell lysates were immunoblotted with the
indicated antibodies.
doi:10.1371/journal.pone.0033891.g001
Table 1. Age, sex, and clinical characteristics of patients 1 to 16.
Patient# NUP age at diagnosis (y) sex clinical features
#1 1506614 7.9 F bone
#2 1506751 9 M bone
#3 2106401 0.26 M skin, lung, lympn node
#4 2106143 0.5 M LETTERER SIWE hematological dysfunction, bone, liver, spleen
#5 1406259 8.4 F bone
#6 1506706 19 M Skin
#7 2106169 0.438 F LETTERER SIWE hematological dysfunction, bone, liver, spleen, pituitary
#8 1406253 8.6 F bone
#9 1406254 7.6 M bone
#10 1406015 0 F LETTERER SIWE hematological dysfunction, bone, liver, spleen, pituitary, lung, lymph
nodes
#11 1406210 10 M bone
#12 1506008 0.97 F LETTERER SIWE hematological dysfunction, bone, lung, liver, spleen
#13 1406215 5.3 M bone
#14 1406247 7.59 F bone, lymph node
#15 1506766 11.79 F bone
#16 1506646 1 M skin, bone
doi:10.1371/journal.pone.0033891.t001
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(CD142), at a high frequency of 37 to 45% relative mutation
abundance, respectively, similar to its abundance in the granuloma
(Table 2). This pattern suggested a germ-line mutation. Conven-
tional ‘Sanger’ sequencing of peripheral blood mononuclear cells
from the patient and from the patient’s mother with an Applied
Biosystem Genetic analyzer 3730xl confirmed the presence of an
allelic mutation (Figure 1 B). Therefore the
T599AB-RAF mutation
was present in the peripheral blood of the patient and his mother,
indicating a germ-line transmitted allele (Figure 1 C).
Altogether, these data indicate that
V600EB-RAF and
600DLATB-
RAF are somatic events while
T599AB-RAF is a germ-line
polymorphism.
B-RAF 600DLAT is an activating B-RAF mutant
Substitution of Val600 with Glu (
V600EB-RAF) strongly activates
B-RAF [28,29].
600DLATB-RAF is an in-frame insertion of 12
nucleotides leading to the insertion of 4 amino acids (Asp-Leu-Ala-
Thr, or DLAT) starting from position 600 (Figure 1 A). This
insertion, in the structural alignment superimposed to the V600
position, therefore effectively results in a B-RAFV600D substitu-
tion, leaving the insertion constituted only by a LATV segment.
We have examined the residues surrounding D600 in the structure
within a cut-off range of 6 A ˚. As reported by Wan et al. [29] the
V600 residue is in a cluster of hydrophobic residues with Phe468,
therefore the presence of a negative charge (residue D) will disrupt
this cluster, resulting in destabilization of the inactive conforma-
tion of
600DLATB-RAF, exactly as for the V600E mutant (Figure 1
D–F). As expected from our structural modelisation study,
600DLATB-RAF resulted in increased MEK and ERK activation
upon transient transfection in 293 T cells in comparison to wild-
type B-RAF, similar to what is observed for
V600EB-RAF [29]
(Figure 1). However, we could not investigate the role of
V600EB-
RAF and
600DLATB-RAF in myeloid cells, since, when transfected
in U937 and THP1 myeloid cell lines both
V600EB-RAF and
600DLATB-RAF resulted in growth arrest and cell death (data not
shown).
B-RAF T599A is a dead-kinase B-RAF mutant that does
not transactivate C-RAF
Thr599 is a major phosphorylation site in the B-RAF activation
domain [28], and substitution of Thr599 with alanine was shown
in vitro to suppress B-RAF activity. Indeed, in contrast to
V600EB-
RAF and
600DLATB-RAF,
T599AB-RAF substitutes a polar
uncharged residue with a hydrophobic residue, causing the loss
of short-ranged interactions with residues D576 and D594
(Figure 1 A, B). This does not predict a destabilization of the
inactive conformation of B-RAF. Indeed transfection of
T599AB-
RAF in 293 T cells did not increase MEK and ERK phosphor-
ylation, in comparison to wt control (Figure 1 G). Co-transfection
of C-RAF did not increase MEK and ERK phosphorylation in the
presence of
T599AB-RAF (Figure 1 H). To further investigate the
function of
T599AB-RAF in myeloid cells, we retrovirally
transfected
wtB-RAF and
T599AB-RAF in THP1 myeloid cells.
As shown in Figure 2 C and 2 D
T599AB-RAF did not induce
MEK and ERK phosphorylation in THP1 cells above control
(Figure 2 C). Thus
T599AB-RAF may represent a mutant devoid of
intrinsic kinase activity.
However, some B-RAF mutants found in cancer such as
D594AB-RAF, albeit devoid of intrinsic B-RAF kinase activity, can
transactivate C-RAF and the MEK/ERK pathway [30,31]. We
thus compared the activity of
T599AB-RAF with that of
wtB-RAF
and
D594AB-RAF after retroviral transfection into U937 cells.
Results indicated that unlike
D594AB-RAF,
T599AB-RAF did not
induce MEK/ERK phosphorylation (Figure 2 D, E) or IL-8
production (Figure 2 F) by U937 cells.
Table 2. Presence and relative abundance of B-RAF mutant clones identified in granuloma and blood from patients with LCH.
granuloma
total gDNA cDNA blood, gDNA
Patient# NUP gDNA CD1a+ effluent CD1a+ effluent
whole
blood CD14+ CD142
#1 1506614 V600E 13,5% wt wt wt
#2 1506751 V600E 29,4% wt
#3 2106401 V600E 16%
#4 2106143 V600E 35% V600E 40%
#5 1406259 V600E 38% V600E 22% V600E 46% V600E 24%
#6 1506706 V600E 8%
#7 2106169 V600E 9%
#8 1406253 V600E 21% V600E 8% V600E 48% V600E 6%
#9 1406254 V600E 35% V600E 23% V600E 47% V600E 35%
#10 1406015 600DLAT 11% 600DLAT 5% 600DLAT 28% 600DLAT 11%
#11 1406210 wt
#12 1506008 wt
#13 1406215 wt
#14 1406247 wt
#15 1506766 wt wt wt
#16 1506646 T599A 44% T599A 37% T599A 37% T599A 45%
doi:10.1371/journal.pone.0033891.t002
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V600EB-RAF mutations were found both in children with
granuloma of bones or isolated skin disease, and in infants with
early-onset multi-organ disease (Table 1). Among the 16 studied
patients, we compared the proportion of patients with or without
B-RAF mutations according to the extension of the disease by
Fisher exact test and according to the age of diagnosis by
Kruskall Wallis Test. No significant difference was observed as
the p value was above 0.05 for all tests. However the sample size
was small and may not be representative of a population based
sample of patients. The patient with a
600DLATB-RAF insertion
presented with early-onset multi-organ disease, but responded
well to treatment (Patient #10, Table 1). The patient with a
germ-line
T599AB-RAF allele (Patient #16, Table 1) presented at
the age of 10 months with persistent swelling of the left parietal
bone. Two months after, clinical examination revealed 10 small
skin nodules. Biopsy of one skin element demonstrated the
histological diagnosis of LCH with the presence of CD1a+ cells.
Patient #16 received therapy by vinblastine and steroid, as per
the LCH III protocol, for a total duration of one year. No
reactivation of the disease or sequellae was observed during a 7-
year follow-up. His mother, who carried the same allelic
mutation, is in good health and did not report a personal
history of LCH.
Discussion
In this study we confirm the findings by Badalian-Very et al.
[20], that
V600EB-RAF mutations are detected in LCH granuloma,
and identify two additional mutations
600DLATB-RAF and
T599AB-
RAF in two LCH patients. The
600DLATB-RAF mutants mimics
V600EB-RAF at the structural and functional level. Our results also
indicate that
V600EB-RAF and
600DLATB-RAF mutations are
enriched in CD1a+ ‘LCH’ granuloma cells and absent from the
blood of 58 patients, suggesting the presence of somatic mutations
in CD1a+ cells, and arguing against a mosaicism in the myeloid
lineage or a bone marrow clonal disease, within the sensitivity
limits of our deep-sequencing assay. We also identified a novel
germ-line
T599AB-RAF polymorphism in a patient with LCH,
although it remains unclear whether
T599AB-RAF is involved in
the pathophysiology of LCH in this patient. The data presented
here strengthen the association between B-RAF mutation and a
dysregulation of the RAS-RAF-MEK pathway in CD1a+ LCH
cells from LCH granuloma.
Both the study by Badalian-Very [20] and our present report
fail to show a correlation between the presence of B-RAF
mutations in LCH granuloma and the patient’s age, clinical
presentation, or outcome. However, the total number of cases
analysed reported (77 in total) is still too small to allow a powerful
Table 3. Age, sex, clinical features, and molecular findings in 22 patients with available blood samples at the time of diagnosis or
relapse.
patient # NUP Clinical features status at the time of blood sample BRAF
whole blood CD14+ CD142
#17 1406220 bone skin, ENT, pituitary, neuro active/progressive disease na wt wt
#18 1506752 skin active/progressive disease wt na na
#19 1506604 Bone, skin, hematological dysfunction active/progressive disease wt na na
#20 1506648 Bone, skin, ENT, lung, liver,
hematological dysfunction
active/progressive disease wt na na
#21 1506882 Skin, ENT active/progressive disease wt na na
#22 1506863 Bone, skin, ENT, lung, liver,
hematological dysfunction
active/progressive disease wt na na
#23 1506009 Bone, skin, ENT, nodes, pituitary, lung,
liver, spleen, hematological dysfunction
active/progressive disease wt na na
#24 1507109 skin, ENT, pituitary active/progressive disease wt na na
#25 2106005 Bone, skin, ENT, CNS mass lesion active/progressive disease wt na na
#26 1509003 bone at diagnosis, before treatment wt na na
#27 1506819 bone at diagnosis, before treatment wt na na
#28 1507093 bone at diagnosis, before treatment wt wt na
#29 1506957 lung at diagnosis, before treatment wt na na
#30 1506973 bone, pituitary at diagnosis, before treatment wt na na
#31 1507062 Skin at diagnosis, before treatment wt wt wt
#32 1506869 bone 1 MONTH DIAGNOSIS wt na na
#33 1507096 bone ,2 MONTH DIAGNOSIS na wt wt
#34 1506754 skin 2 MONTHS DIAGNOSIS wt na na
#35 1506865 bone 2 MONTH DIAGNOSIS wt na na
#36 1507084 skin 2 MONTH DIAGNOSIS wt wt wt
#37 1506932 bone 3 MONTH DIAGNOSIS wt wt na
#38 1506984 skin 3 MONTH DIAGNOSIS wt na na
doi:10.1371/journal.pone.0033891.t003
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disease [1,4,5]. A statistical study of the possible association or lack
of association of B-RAF somatic mutations with subgroups of
LCH patients or with the natural history of the disease remains to
be done, in a population based approach.
Our results indicate that both
600DLATB-RAF and
V600EB-RAF
mutations are somatic events which are not detected in the blood
of patients. LCH granulomas may thus arise from a local process
within affected tissues, rather than from the continuous recruit-
ment of putative precursors, such as monocytes or dendritic cells
carrying activating B-RAFV600E or B-RAF600DLAT alleles.
Nevertheless, given the threshold sensitivity of 1%–2% of our
deep-sequencing method, we cannot exclude the contribution of a
minor myeloid-restricted clone in the bone marrow of patients, or
of a subset of patients, and a prospective investigation is required
to further investigate whether detection of rare circulating or bone
marrow B-RAF mutated cells may be useful to monitor residual
disease.
While substitution of Val600 with Glu (
V600EB-RAF) strongly
activates B-RAF, substitution of Thr599 with Ala (
T599AB-RAF)
impairs B-RAF kinase activity [28,29] given that Thr599 is the
major phosphorylation site in the B-RAF activation domain [28].
Other mutations that affect intrinsic B-RAF kinase activity such as
D594AB-RAF can also transactivate C-RAF and the MEK/ERK
pathway, albeit less strongly [30,31]. However we have shown
here that
T599AB-RAF was both impaired in its intrinsic B-RAF
kinase activity and unable to transactivate C-RAF. At this time, we
do not have a molecular explanation for this observation. Further
studies will therefore be needed to potentially unveil the functional
consequences of the
T599AB-RAF allele on cell activation. The
patient’s mother born in 1977 carried the same B-RAFT599A
allele while in good health, and without a personal history of LCH.
Therefore, although the
T599AB-RAF allele is not a common
polymorphism, there is no evidence that
T599AB-RAF is involved
in the pathophysiology of LCH in our patient. However the
clinical spectrum of LCH is remarkably broad, and the age of
onset highly variable [1,4,5], preventing us to definitely conclude
to the absence of LCH in the mother of the patient. For instance,
in one previously reported case of familial LCH, a monostotic
lesion was diagnosed in a 20-year-old woman and then also in her
daughter when aged 30 months [32].
Finally,
V600EB-RAF mutations are observed in a number of
benign and tumoral diseases (e.g. naevi and melanoma [25,26]). In
itself this mutation thus do not characterize a malignant disease. It
is posssible that the effects of activating B-RAF mutations such as
V600EB-RAF and
600DLATB-RAF are different whenever they
occur in stem cells or and differentiated cells, and depending on
the lineage of the mutated cells, i.e. epithelial or myeloid.
Therefore, more work is needed to understand the consequences
of
V600EB-RAF and
600DLATB-RAF in myeloid cells. We observed
that retroviral transduction of either
V600EB-RAF or
600DLATB-
RAF in U937 and THP1 myeloid cell lines resulted in growth
arrest and cell death. This suggests that an in vivo approach may
be preferable, since an appropriate cellular environment could be
required to support cell growth of
V600EB-RAF or
600DLATB-RAF
expressing myeloid cells. In this regard, mouse models of
conditional expression of B-RAF mutant alleles in different cell
lineages [23], should prove extremely useful.
Materials and Methods
Patients
Patients were registered in the National French Registry for
Langerhans Cell Histiocytosis. LCH diagnosis was established on
the basis of the patients’ clinical history, histological examination
and the mandatory presence of CD1a+ histiocytes in clinical
Figure 2. Analysis of
T599AB-RAF. (A, B) Comparison between models of
WTB-RAF 5P_15056 (A, violet) and
T599AB-RAF (B, gold).
T599AB-RAF
substitutes a polar uncharged residue with a hydrophobic residue, causing the loss of short-ranged interactions with residues D576 and D594. C.
Analysis of MEK and ERK phosphorylation in THP1 cell lines stably transfected with
WTB-RAF-FLAG and
T599AB-RAF-FLAG. Experiment was repeated
twice with similar results. (D–F) Analysis of MEK and ERK phosphorylation and IL-8 production in U937 cell lines stably transfected with
WTB-RAF,
T599AB-RAF, and
D594AB-RAF. Experiment was repeated twice with similar results.
doi:10.1371/journal.pone.0033891.g002
B-RAF Mutant Alleles in LCH
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e33891biopsy specimens, and reviewed by a national panel of
pathologists. Patient’s parents gave written informed consent for
the study. The Study was approved by the Institutional Review
Board of the University Hospital of Nantes, France. Characteristic
of patients 1–16 are summarized in Table 1. Biopsies samples
and/or blood were obtained at diagnosis from 15 patients with
various clinical forms of the disease, isolated involvement of bone
(n=9), early-onset multisystem disease (n=4), isolated skin (n=1)
and skin and lung disease (n=1) (Table 1). Purified CD1a+ cells
were isolated from biopsies from patients with eosinophilic
granuloma of bone (n=3) and early-onset multisystem disease
(n=3). Blood was obtain from patient 16 and his parents, and
epithelial cells from patient 16, his parents and brother.
Preparation of DNA from granuloma samples, whole
blood, and purified cellular fractions
Samples from CD1a+ LCH cells were obtained as previously
described [8]. In brief, after frozen section examination, sterile
tissue from eosinophilic granuloma was harvested in RPMI 1640
supplemented with 2 mM L-glutamine, 100 U/mL penicillin,
100 mg/mL streptomycin, and 10% heat-inactivated fetal calf
serum (FCS) myoclone (all from GIBCO BRL, Gaithersburg,
MD), referred to below as complete medium. Tissues were
immediately gently dissociated through a nylon mesh. The cell
suspension was washed 3 times and incubated with human IgG to
block Fc receptor, and anti-CD1a antibody (BL6; Immunotech,
Marseille, France). The cells were washed twice, incubated with
antimouse microbeads (MACS; Miltenyi Biotec, Bergisch Glad-
bach, Germany) for 15 minutes at 4uC. Cells were washed again,
and then CD1a+ LCH cells were separated by positive
immunomagnetic selection by using a magnetic cell separator
(MACS) according to the manufacturer’s instructions. Between
2.105 and 6.105 CD1a+ cells were recovered from each sample.
Purity of CD1a+ and CD1alow/neg sorted fraction was 80% or
greater and mortality 10% or less. Genomic DNA and RNA from
frozen granuloma cells, sorted CD1a+ cells and effluent fractions
lysed and stored in Trizol were extracted using chloroform, the
organic phase was transferred to a fresh tube to extract genomic
DNA, and RNA was extracted using the RNA microkit from
Qiagen. cDNA was obtained using the Superscript III Reverse-
transcriptase kit (Invitrogen) according to the manufacturer’s
procedure. Genomic DNA extraction from paraffin sections
(Patient 16) was performed as per Qiagen protocol for this
material. Genomic DNA extraction from whole Blood was
performed using the GenElute Blood genomic DNA kit mini prep
from Sigma Aldrich according to the manufacturer procedure.
Peripheral blood mononuclear cells (PBMCs) were obtained by the
standard Ficoll-Hypaque method. CD14+ and CD142 fraction
were separated by negative magnetic depletion by using hapten-
conjugated CD3, CD7, CD19, CD45RA, CD56, and anti-IgE
antibodies (MACS; Miltenyi Biotec) and a MACS according to the
manufacturer’s instructions. gDNA and RNA were extracted from
CD14+ and CD142 MACS purificated monocytes fractions using
the RNA/DNA AllPrep QIAgen Minikit (Quiagen).
B-RAF mutation detection
Pyrosequencing assay was performed using with 454 sequencing
(Roche GS FLX platform). Primers sets were designed to amplify
B-RAF exons 11 and 15 from both genomic DNA and cDNA,
which incorporated a universal forward and reverse sequence tag.
A second round of PCR was also performed utilizing the universal
tags, to incorporate a sample specific 10 bp ‘‘barcode’’ sequence as
well as additional tags utilized in the sequencing process (Roche
GS FLX Titanium). Sequencing was performed to yield a ‘depth’
in excess of 500 clonal reads (5006) per exonic amplicon, per
patient sample in most cases. This allowed detection of mutant
clones down to around 1–2% relative mutation abundance,
defined as the proportion of sequence reads that contain the
mutation. Independent PCR and GS FLX sequencing experi-
ments were carried out to confirm mutations and to reduce
sampling error for calculations of mutation abundance. Somatic
mutation in patient #16, his parents and his sibling were
confirmed using a Applied Biosystem Genetic analyzer 3730xl
(primers available on request).
B-RAF mutation modeling
The B-RAF patient mutations
600DLATB-RAF and
T599AB-RAF
have been modeled starting from the structure of the B-RAF
kinase domain [29] using the Modeller 9v8 program [33]. The
sequence alignment on this domain with the observed patient
mutations was performed with the program Praline [34]. The
structural alignment of the mutated sequences with the chosen
template (pdb code 1WUH) was performed with the program T-
coffee [35]. For each mutant, 200 structures have been generated
and the ones with the best DOPE score have been selected for
further investigations. The VMD program [36] has been used for
graphical representations and for structural analyses.
Transfection of B-RAF alleles in 293 T cells
293 T (Lenti-X 293 T) was purchased from Clontech, and
maintained in DMEM supplemented with 10% FBS, 100 units/ml
Penicillin, and 100 mg/ml Streptomycin. cDNA fragments of
human B-RAF (Genbank accession number: NM_004333) and C-
RAF (Genbank accession number: NM_002880) were amplified
by RT-PCR from human PBMC cDNA and cloned into pMXs-
puro vector. V600E, T599A, D594A, and G596R B-RAF mutants
construct were obtained by site-direct mutagenesis (Agilent
Technologies). DLAT insertion B-RAF mutant construct was
generated by PCR. The constructs were FLAG-tagged and cloned
into pMXs-puro and pMXs-IRES-GFP vectors. The mutations
were confirmed by DNA sequencing.
293 T was transiently transfected with pMXs-puro, FLAG-B-
RAF WT, V600E, T599A, 600DLAT, D564A, G596R, or FLAG-
CRAFvectors as indicated in the figure. Transfection was carried
out with jetPEI according to the manufacture’s instructions
(Polyplus transfections, Inc.).
Generation of stable B-RAF transfectants using retroviral
vector
Retrovirus packaging cell line, Plat-A was purchased from Cell
Biolabs, Inc., and maintained in DMEM supplemented with 10%
FBS, 100 units/ml Penicillin, and 100 mg/ml Streptomycin.
U937 was kindly donated by Dr. Taams. THP-1 was kindly
donated by Dr. Neil. These cell lines were maintained in RPMI
supplemented with 10% FBS, 100 units/ml Penicillin, and
100 mg/ml Streptomycin (complete medium). Plat-A was tran-
siently transfected with pMXs-IRES-GFP, FLAG-B-RAF WT,
V600E, T599A, 600DLAT, D594A, and G596R vectors using
jetPEI. Twenty-four hours after transfection, the medium was
changed to fresh DMEM, and the cells were cultured for further
24 hours. The virus supernatants were collected and the debris
was removed by centrifuge. The supernatants were mixed with
DOTAP Liposomal Transfection Reagent (Roche) and added to
U937 or THP-1 culture, followed by centrifuge at 30uC at 11006g
for 2 hours. Forty-eight hours after infection, GFP positive cells
were sorted using BD FACSAria (BD Biosciences) and maintained
in complete medium.
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Twenty-four hours after transfection to 293 T cells, culture
medium was changed to serum-free DMEM and cells starved for
18 hours. Cells were lysed with RIPA buffer (20 mM Tris-HCl
(pH7.4), 150 mM NaCl, 2 mM EDTA, 1% Nonidet-P 40, 0.1%
Sodium dodecyl sulfate, 0.1% Sodium deoxycolate, 50 mM
Sodium fluoride, 1 mM b-Glycerophosphate, 1 mM Sodium
orthovanadate, 1 mM Phenylmethylsulfonyl fluoride, and Prote-
ase inhibitor cocktail (Sigma-Aldrich)). For the experiment using
THP-1 transfectant, 1610
6 of growing cells were colllected by
centrifuge and lysed in RIPA buffer. The cell lysates were
separated on 10% SDS-PAGE gel and transferred onto nitrocel-
lulose membranes (Bio-Rad). The membrane were blotted with
anti-phospho-MEK1/2 mAb (41G9), anti-MEK1/2 mAb
(L38C12), anti-phospho-ERK1/2 (D13.14.4E), anti-ERK1/2
mAb (L34F12) all from Cell Signaling Technology, Inc., and
anti-FLAG M2 (Sigma Aldrich). Horseradish peroxidase-coupled
secondary antibodies were used to detect the primary antibodies.
Signal was revealed by enhanced chemiluminescence (SuperSignal
West Pico Chemiluminescent Substrate, Pierce) using a molecular
imager Chemidoc
TM XRS+, Biorad. Band intensity was quanti-
fied by ImageLab
TM Analysis Software.
Quantification of pMEK, pERK, and IL-8 from U937
transfectant by Bio-Plex
For the measurement of IL-8 secretion, 16104 of U937
transfectants ware laid in a 96 well plate in 100 microL. After
24 hours, the plate were centrifuged and supernatants were
collected. For pMEK and pERK, 16104 of U937 were lysed using
Bio-Plex Cell Lysis kit. The samples were analyzed according to
manufactures instructions.
Statistics
Unsupervised students t-test on single comparisons was
compared to analyse significance. A P value,0.05 was considered
significant.
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